DE69034000D1 - Ranolazine and related piperazines to protect skeletal muscles - Google Patents

Ranolazine and related piperazines to protect skeletal muscles

Info

Publication number
DE69034000D1
DE69034000D1 DE69034000T DE69034000T DE69034000D1 DE 69034000 D1 DE69034000 D1 DE 69034000D1 DE 69034000 T DE69034000 T DE 69034000T DE 69034000 T DE69034000 T DE 69034000T DE 69034000 D1 DE69034000 D1 DE 69034000D1
Authority
DE
Germany
Prior art keywords
ranolazine
piperazines
skeletal muscles
protect skeletal
protect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69034000T
Other languages
German (de)
Other versions
DE69034000T2 (en
Inventor
Robert J Dow
Pierre Ferrandon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of DE69034000D1 publication Critical patent/DE69034000D1/en
Application granted granted Critical
Publication of DE69034000T2 publication Critical patent/DE69034000T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Piperazine derivatives, particularly ranolazine, are useful for treatment of tissues experiencing a physical or chemical insult, and specifically for treating shock conditions.
DE69034000T 1989-06-23 1990-06-21 Ranolazine and related piperazines to protect skeletal muscles Expired - Lifetime DE69034000T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37043589A 1989-06-23 1989-06-23

Publications (2)

Publication Number Publication Date
DE69034000D1 true DE69034000D1 (en) 2002-10-10
DE69034000T2 DE69034000T2 (en) 2003-06-05

Family

ID=23459660

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69034000T Expired - Lifetime DE69034000T2 (en) 1989-06-23 1990-06-21 Ranolazine and related piperazines to protect skeletal muscles
DE69033967T Expired - Lifetime DE69033967T2 (en) 1989-06-23 1990-06-21 Ranolazine and related piperazines for the treatment of shock conditions
DE69028457T Expired - Lifetime DE69028457T2 (en) 1989-06-23 1990-06-21 Ranolazine and related piperazines used to treat tissues affected by physical or chemical damage

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69033967T Expired - Lifetime DE69033967T2 (en) 1989-06-23 1990-06-21 Ranolazine and related piperazines for the treatment of shock conditions
DE69028457T Expired - Lifetime DE69028457T2 (en) 1989-06-23 1990-06-21 Ranolazine and related piperazines used to treat tissues affected by physical or chemical damage

Country Status (13)

Country Link
US (2) US5506229A (en)
EP (3) EP0719558B1 (en)
JP (1) JP3232085B2 (en)
AT (3) ATE223218T1 (en)
AU (1) AU633589B2 (en)
CA (1) CA2019580C (en)
DE (3) DE69034000T2 (en)
DK (3) DK0719558T3 (en)
ES (3) ES2182863T3 (en)
GR (1) GR3020976T3 (en)
IE (1) IE80710B1 (en)
NZ (2) NZ234184A (en)
ZA (1) ZA904842B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
ATE318595T1 (en) 1997-08-08 2006-03-15 Univ Duke COMPOSITIONS FOR SIMPLIFYING SURGICAL PROCEDURES
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
EP1259230A2 (en) * 2000-02-18 2002-11-27 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
CA2657986A1 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
US6638970B2 (en) 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
AU2001285245A1 (en) * 2000-08-25 2002-03-13 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
IL165304A0 (en) * 2002-05-21 2006-01-15 Cv Therapeutics Inc Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP1567525B1 (en) 2002-12-05 2007-06-27 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
ATE443058T1 (en) 2003-01-03 2009-10-15 Cv Therapeutics Inc SUBSTITUTED HETEROCYCLIC COMPOUNDS
AU2004209522A1 (en) 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
EP1644345A1 (en) 2003-06-23 2006-04-12 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
KR20060124646A (en) 2003-12-18 2006-12-05 씨브이 쎄러퓨틱스, 인코포레이티드 1-akan-2-ol substituted piperazine and piperidine compounds
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
CN101072562A (en) * 2004-11-09 2007-11-14 Cv医药有限公司 Use ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
AU2006203890A1 (en) * 2005-01-06 2006-07-13 Gilead Sciences, Inc. Sustained release pharmaceutical formulations comprising ranolazine
JP2008533044A (en) * 2005-03-11 2008-08-21 ホン コン ナイトリック オキサイド リミテッド Combination therapy for endothelial dysfunction, angina and diabetes
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
EP2117508A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Intravenous solutions comprising ranolazine
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
ES2402675T3 (en) * 2007-05-31 2013-05-07 Gilead Palo Alto, Inc. Ranolazine for the brain-type natriuretic peptide at elevated levels
BRPI0908428A2 (en) * 2008-02-06 2015-12-08 Gilead Sciences Inc use of ranozaline to treat pain.
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
EP2515880B1 (en) 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
AU2015200961B2 (en) * 2009-07-09 2017-02-16 Ozteo Pty Ltd Treatment of Non-Neuronal and Non-Cardiac Cell, Tissue and Organ Damage and Associated Pain with Persistent Sodium Current Blockers
WO2011003129A1 (en) * 2009-07-09 2011-01-13 Ozteo Pty Ltd Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers
EP2480234B1 (en) 2009-09-25 2020-02-26 Lupin Limited Sustained release composition of ranolazine
TWI508726B (en) 2009-12-21 2015-11-21 Gilead Sciences Inc Method of treating atrial fibrillation
WO2012170676A1 (en) * 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101476379B1 (en) * 2011-11-30 2014-12-29 한국과학기술연구원 Derivatives of 1-Phenoxy propan-2-ol and pharmaceutical composition containing the same
KR101331186B1 (en) * 2013-08-05 2013-11-22 한국과학기술연구원 Derivatives of 1-Phenoxy propan-2-ol and pharmaceutical composition containing the same
AU2022350543A1 (en) * 2021-09-27 2023-05-04 Tasly Pharmaceutical Group Co., Ltd. Pharmaceutical composition for treating myocardial ischemia and preparation method therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Also Published As

Publication number Publication date
DE69033967D1 (en) 2002-07-11
EP0407780A3 (en) 1992-01-02
EP0407780B1 (en) 1996-09-11
NZ234184A (en) 1997-01-29
DK0407780T3 (en) 1996-09-30
CA2019580A1 (en) 1990-12-23
GR3020976T3 (en) 1996-12-31
JP3232085B2 (en) 2001-11-26
EP0719558A1 (en) 1996-07-03
US5506229A (en) 1996-04-09
DK0719558T3 (en) 2002-10-07
EP0714660A1 (en) 1996-06-05
IE902250A1 (en) 1991-01-16
DE69028457T2 (en) 1997-02-20
AU5761890A (en) 1991-01-03
IE902250L (en) 1990-12-23
EP0719558B1 (en) 2002-06-05
EP0407780A2 (en) 1991-01-16
US5906988A (en) 1999-05-25
DE69028457D1 (en) 1996-10-17
DE69034000T2 (en) 2003-06-05
CA2019580C (en) 2007-03-27
AU633589B2 (en) 1993-02-04
JPH0348672A (en) 1991-03-01
ATE223218T1 (en) 2002-09-15
DE69033967T2 (en) 2002-12-19
ES2091211T3 (en) 1996-11-01
ES2182863T3 (en) 2003-03-16
IE80710B1 (en) 1998-12-16
EP0714660B1 (en) 2002-09-04
ATE218344T1 (en) 2002-06-15
ES2177601T3 (en) 2002-12-16
NZ247044A (en) 1997-04-24
ATE142497T1 (en) 1996-09-15
DK0714660T3 (en) 2002-10-07
ZA904842B (en) 1992-02-26

Similar Documents

Publication Publication Date Title
DE69034000T2 (en) Ranolazine and related piperazines to protect skeletal muscles
ES2169127T3 (en) NEW CARBAMATES AND UREAS AS MODIFIERS OF THE MULTI-FARMACO RESISTANCE.
DE69725293D1 (en) N- (2 OXOACETYL OR SULPHONYL) -PYRROLIDINE / PIPERIDINE-2-CARBONIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY
PL287618A1 (en) Method of obtaining 4- i 6-carbaminates related to physostygmine
DE69715862D1 (en) USE OF A K-252A DERIVATIVE FOR TREATING PERIPHERAL OR CENTRAL NERVOUS DISEASES AND EXCESSIVE CYTOKINE FORMATION
ES476524A1 (en) Novel cinnamoyles piperazines and homopiperazines, the method of preparing them and their application in therapeutics
ATE111908T1 (en) ANTI-ALLERGIC BENZOTHIOPHENE AND NEW AND OTHER SELECTED BENZOTHIOPHENE, BOTH ACTIVE TO TREAT ACUTE RESPIRATORY ANXIETY SIGNS.
ES8801505A1 (en) Heterocyclic sulfides, process for their preparation and Medicaments containing them.
DE3063946D1 (en) Pesticidal agents containing substituted benzazoles and application thereof
ES460600A1 (en) Aminoalkoxybenzofurans
NO781758L (en) PROCEDURES FOR INACTIVATION OF IONIZABLE SULFID IN A WELL DRILLING BAG
DE59509068D1 (en) CATIONIC AGENTS FOR FATING LEATHER AND FUR
ES8303306A1 (en) N-(aryloxyalkyl)-N'-(amino-alkyl) ureas.
ATE232734T1 (en) USING PVP OR POVIDONE TO REDUCE INTESTINAL SWELLING
IT8921990A0 (en) N,N'-DI-(TRIMETHOXYBENZOIL) SUBSTITUTED 2-METHOXYCARBONIL PIPERAZINES, PROCEDURE FOR PREPARING THEM AND THERAPEUTIC COMPOUNDS THAT CONTAIN THEM
DE3770481D1 (en) USE OF IMIDAZOCHINAZOLINES FOR TREATING AND PREVENTING NEPHRITIS.
DE3684825D1 (en) USE OF N- (1-ALLYL-2-PYRROLIDINYLMETHYL) -2-METHOXY-4-AMINO-5-METHYLSULFAMOYLBENZAMIDE FOR TREATING PARKINSON'S DISEASE.
FR2451372A1 (en) N- (2-3-BENZOYLPHENYL) PROPIONYLETHYLENEDIOXYETHYL) -N '- (4-CHLOROBENZHYDRYL) PIPERAZINE, ITS PREPARATION AND ITS THERAPEUTIC USE
JPS57150303A (en) Working machine for harrowing and leveling paddy field of tractor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition